T1G3 bladder tumours: the case for radical cystectomy
- PMID: 15041102
- DOI: 10.1016/j.eururo.2003.11.007
T1G3 bladder tumours: the case for radical cystectomy
Abstract
Introduction: Many factors degrade the initially favourable results of conservative treatment of T1G3 bladder tumours, leading to a permanent risk of progression and death. On the other hand, immediate radical cystectomy, while ensuring optimal local control of the disease, would be excessive in some patients in part because of its purported impact on quality of life.
Methods: To contribute to the ongoing debate on T1G3 optimal treatment the literature was reviewed to organize evidences in favour of radical cystectomy by focusing on two main issues: the impact of time on the initial results of conservative treatment and quality of life after cystectomy.
Results: A critical appraisal of conservative treatment efficacy was structured by comparing survival curves after either conservative treatment or radical cystectomy. It highlighted that after conservative treatment the patients remained under the burden of lifelong risk of progression and death. The positive impact of maintenance BCG and the frequent resort to cystectomy after conservative treatment further illustrated the limits of bladder conservative treatments. On the other hand, evidences were shown that quality of life was not critically affected by radical cystectomy and that surgical techniques could be further adapted to its preservation. The influence of age at cystectomy on functional results was highlighted. However, identifying a prognostic factor for the success of conservative treatment would put an end to the controversy by allowing a tailored attitude to every patient's unique situation. The importance of uropathologist's expert evaluation, including the depth of invasion, was emphasized.
Conclusion: While ensuring optimal control of the disease, the indiscriminate use of radical surgery would be excessive in a significant minority of patients who do well under conservative treatment. It is suggested to consider as typical cases for immediate surgery, young patients with "deep" T1 tumours (>T1a or >1.5mm in depth) with at least one additional factors of bad prognosis: multifocality, association of carcinoma-in-situ, prostatic involvement, site difficult to resect.
Comment in
-
T1G3 bladder cancer: conservative management or cystectomy?Eur Urol. 2004 Apr;45(4):399-400. doi: 10.1016/j.eururo.2003.11.027. Eur Urol. 2004. PMID: 15041100 No abstract available.
Comment on
-
T1G3 bladder tumours: the case for conservative treatment.Eur Urol. 2004 Apr;45(4):401-5. doi: 10.1016/j.eururo.2003.11.008. Eur Urol. 2004. PMID: 15041101 Review. No abstract available.
Similar articles
-
Optimal management of high-risk T1G3 bladder cancer: a decision analysis.PLoS Med. 2007 Sep;4(9):e284. doi: 10.1371/journal.pmed.0040284. PLoS Med. 2007. PMID: 17896857 Free PMC article.
-
[Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].Aktuelle Urol. 2008 Jan;39(1):58-61; discussion 62-3. doi: 10.1055/s-2007-980147. Aktuelle Urol. 2008. PMID: 18228189 German.
-
Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer.Cancer. 2009 Dec 1;115(23):5450-9. doi: 10.1002/cncr.24634. Cancer. 2009. PMID: 19685529
-
What is the significance of pT0 at cystectomy?Surg Oncol. 2006 Aug;15(2):65-9. doi: 10.1016/j.suronc.2006.07.005. Epub 2006 Sep 12. Surg Oncol. 2006. PMID: 16971115 Review.
-
Optimal management of the T1G3 bladder cancer.Urol Clin North Am. 2005 May;32(2):133-45. doi: 10.1016/j.ucl.2005.02.002. Urol Clin North Am. 2005. PMID: 15862611 Review.
Cited by
-
Usefulness of pT1 substaging in papillary urothelial bladder carcinoma.Diagn Pathol. 2016 Jan 20;11:6. doi: 10.1186/s13000-016-0466-6. Diagn Pathol. 2016. PMID: 26791567 Free PMC article.
-
Abnormal expression of multiple proteins predicts cancer-specific mortality in patients with high-grade non-muscle-invasive bladder cancer treated with transurethral resection.Mol Clin Oncol. 2013 May;1(3):473-479. doi: 10.3892/mco.2013.92. Epub 2013 Mar 14. Mol Clin Oncol. 2013. PMID: 24649194 Free PMC article.
-
Prospective Validation of the ROL System in Substaging pT1 High-Grade Urothelial Carcinoma: Results from a Mono-Institutional Confirmatory Analysis in BCG Treated Patients.Cancers (Basel). 2023 Feb 1;15(3):934. doi: 10.3390/cancers15030934. Cancers (Basel). 2023. PMID: 36765894 Free PMC article.
-
Survival after primary and deferred cystectomy for stage T1 transitional cell carcinoma of the bladder.Urol Ann. 2011 Sep;3(3):127-32. doi: 10.4103/0974-7796.84960. Urol Ann. 2011. PMID: 21976924 Free PMC article.
-
High-risk non-muscle-invasive bladder cancer: update for a better identification and treatment.World J Urol. 2012 Dec;30(6):833-40. doi: 10.1007/s00345-012-0967-1. Epub 2012 Oct 16. World J Urol. 2012. PMID: 23070534 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials